Talphera (NASDAQ:TLPH) Stock Price Down 1.9% – Here’s What Happened

Talphera, Inc. (NASDAQ:TLPH) shares were down 1.9% during trading on Friday . The stock traded as low as $0.60 and last traded at $0.60. Approximately 48,096 shares changed hands during trading, a decline of 42% from the average daily volume of 83,511 shares. The stock had previously closed at $0.61.

Wall Street Analyst Weigh In

Several research analysts have commented on TLPH shares. Maxim Group upgraded shares of Talphera to a “strong-buy” rating in a research report on Friday, November 8th. Rodman & Renshaw began coverage on shares of Talphera in a report on Tuesday, January 28th. They set a “buy” rating and a $4.00 price target for the company. HC Wainwright reiterated a “buy” rating and set a $6.00 price target on shares of Talphera in a report on Tuesday, January 21st. Finally, RODMAN&RENSHAW upgraded shares of Talphera to a “strong-buy” rating in a report on Tuesday, January 28th.

Talphera Price Performance

The firm has a market capitalization of $10.23 million, a price-to-earnings ratio of -0.87 and a beta of 0.29. The stock has a fifty day moving average of $0.62 and a two-hundred day moving average of $0.78.

Institutional Trading of Talphera

A hedge fund recently bought a new stake in Talphera stock. Rosalind Advisors Inc. acquired a new stake in Talphera, Inc. (NASDAQ:TLPH) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 758,966 shares of the company’s stock, valued at approximately $650,000. Talphera accounts for 0.4% of Rosalind Advisors Inc.’s investment portfolio, making the stock its 25th largest position. Rosalind Advisors Inc. owned about 4.47% of Talphera at the end of the most recent reporting period. 37.67% of the stock is owned by institutional investors and hedge funds.

About Talphera

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.